700 related articles for article (PubMed ID: 25527197)
1. TRKing down an old oncogene in a new era of targeted therapy.
Vaishnavi A; Le AT; Doebele RC
Cancer Discov; 2015 Jan; 5(1):25-34. PubMed ID: 25527197
[TBL] [Abstract][Full Text] [Related]
2. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA
Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
[TBL] [Abstract][Full Text] [Related]
3. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
4. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
5. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
6. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
7. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
[TBL] [Abstract][Full Text] [Related]
8. TRK inhibitors in TRK fusion-positive cancers.
Drilon A
Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
[TBL] [Abstract][Full Text] [Related]
9. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
Rohrberg KS; Lassen U
Drugs; 2021 Mar; 81(4):445-452. PubMed ID: 33400240
[TBL] [Abstract][Full Text] [Related]
10. Targeting tropomyosin-receptor kinase fused gene in cancer.
Chen Y; Tseng SH
Anticancer Res; 2014 Apr; 34(4):1595-600. PubMed ID: 24692687
[TBL] [Abstract][Full Text] [Related]
11. The trk family of oncogenes and neurotrophin receptors.
Lamballe F; Klein R; Barbacid M
Princess Takamatsu Symp; 1991; 22():153-70. PubMed ID: 1844238
[TBL] [Abstract][Full Text] [Related]
12. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
13. Targeting TRK: A fast-tracked application of precision oncology and future directions.
Kojadinovic A; Laderian B; Mundi PS
Crit Rev Oncol Hematol; 2021 Sep; 165():103451. PubMed ID: 34389458
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
[TBL] [Abstract][Full Text] [Related]
15. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Ardini E; Bosotti R; Amatu A; Valtorta E; Somaschini A; Raddrizzani L; Palmeri L; Banfi P; Bonazzina E; Misale S; Marrapese G; Leone A; Alzani R; Luo D; Hornby Z; Lim J; Veronese S; Vanzulli A; Bardelli A; Martignoni M; Davite C; Galvani A; Isacchi A; Siena S
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355
[TBL] [Abstract][Full Text] [Related]
17. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
Park DY; Choi C; Shin E; Lee JH; Kwon CH; Jo HJ; Kim HR; Kim HS; Oh N; Lee JS; Park OK; Park E; Park J; Shin JY; Kim JI; Seo JS; Park HD; Park J
Oncotarget; 2016 Feb; 7(7):8399-412. PubMed ID: 26716414
[TBL] [Abstract][Full Text] [Related]
18. The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.
Farina AR; Cappabianca L; Ruggeri P; Gneo L; Pellegrini C; Fargnoli MC; Mackay AR
J Exp Clin Cancer Res; 2018 Jun; 37(1):119. PubMed ID: 29914559
[TBL] [Abstract][Full Text] [Related]
19. TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.
Rosen EY; Goldman DA; Hechtman JF; Benayed R; Schram AM; Cocco E; Shifman S; Gong Y; Kundra R; Solomon JP; Bardelli A; Scaltriti M; Drilon A; Iasonos A; Taylor BS; Hyman DM
Clin Cancer Res; 2020 Apr; 26(7):1624-1632. PubMed ID: 31871300
[TBL] [Abstract][Full Text] [Related]
20. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
